Su I, Wang P, Chen C, Huang H, Day Y
Tzu Chi Med J. 2021; 33(4):399-405.
PMID: 34760638
PMC: 8532588.
DOI: 10.4103/tcmj.tcmj_271_20.
Laitano O, Murray K, Leon L
Sports Med. 2020; 50(9):1581-1592.
PMID: 32632746
DOI: 10.1007/s40279-020-01318-4.
J Anesth. 2017; 31(2):307-317.
PMID: 28246924
DOI: 10.1007/s00540-016-2305-z.
Gupta P, Kamal G, Gupta M
J Pharmacol Pharmacother. 2016; 6(4):211-3.
PMID: 26816473
PMC: 4714388.
DOI: 10.4103/0976-500X.171873.
Schneiderbanger D, Johannsen S, Roewer N, Schuster F
Ther Clin Risk Manag. 2014; 10:355-62.
PMID: 24868161
PMC: 4027921.
DOI: 10.2147/TCRM.S47632.
Malignant hyperthermia.
Kim D
Korean J Anesthesiol. 2012; 63(5):391-401.
PMID: 23198031
PMC: 3506847.
DOI: 10.4097/kjae.2012.63.5.391.
Ryanodine receptor channelopathies.
Betzenhauser M, Marks A
Pflugers Arch. 2010; 460(2):467-80.
PMID: 20179962
PMC: 2885589.
DOI: 10.1007/s00424-010-0794-4.
Canine malignant hyperthermia: diagnosis of susceptibility in a breeding colony.
OBrien P, Cribb P, White R, Olfert E, Steiss J
Can Vet J. 1983; 24(6):172-7.
PMID: 17422267
PMC: 1790357.
Identification of novel mutations in the ryanodine-receptor gene (RYR1) in malignant hyperthermia: genotype-phenotype correlation.
Manning B, Quane K, Ording H, Urwyler A, Tegazzin V, Lehane M
Am J Hum Genet. 1998; 62(3):599-609.
PMID: 9497245
PMC: 1376943.
DOI: 10.1086/301748.
To fire the train: a second malignant-hyperthermia gene.
Hogan K
Am J Hum Genet. 1997; 60(6):1303-8.
PMID: 9199549
PMC: 1716108.
DOI: 10.1086/515483.
The G1021A substitution in the RYR1 gene does not cosegregate with malignant hyperthermia susceptibility in a British pedigree.
Adeokun A, West S, Ellis F, Halsall P, Hopkins P, Foroughmand A
Am J Hum Genet. 1997; 60(4):833-41.
PMID: 9106529
PMC: 1712455.
The genetics of malignant hyperthermia.
Ball S, Johnson K
J Med Genet. 1993; 30(2):89-93.
PMID: 8383206
PMC: 1016259.
DOI: 10.1136/jmg.30.2.89.
Dangerous monoamine oxidase inhibitor interactions are still occurring in the 1990s.
Dawson J, Earnshaw S, Graham C
J Accid Emerg Med. 1995; 12(1):49-51.
PMID: 7640830
PMC: 1342519.
DOI: 10.1136/emj.12.1.49.
C1840-T mutation in the human skeletal muscle ryanodine receptor gene: frequency in northern German families susceptible to malignant hyperthermia and the relationship to in vitro contracture response.
Steinfath M, Singh S, Scholz J, Becker K, Lenzen C, Wappler F
J Mol Med (Berl). 1995; 73(1):35-40.
PMID: 7633940
DOI: 10.1007/BF00203617.
Effect of temperature, time and fascicle size on the caffeine contracture test.
Britt B, Endrenyi L, Scott E, Frodis W
Can Anaesth Soc J. 1980; 27(1):1-11.
PMID: 7353184
DOI: 10.1007/BF03006840.
A family with intussusception and malignant hyperthermia.
Jolly D, McKim J, Corrin M
Can Med Assoc J. 1982; 127(8):737-8.
PMID: 7139491
PMC: 1862379.
Comparison of the caffeine skinned fibre tension (CSFT) test with the caffeine-halothane contracture (CHC) test in the diagnosis of malignant hyperthermia.
Britt B, Frodis W, Scott E, Clements M, Endrenyi L
Can Anaesth Soc J. 1982; 29(6):550-62.
PMID: 7139394
DOI: 10.1007/BF03007740.
The in-vitro caffeine contracture test: influence of the muscle histochemical profile on test results.
Brownell A, Szabo M
Can Anaesth Soc J. 1982; 29(3):218-21.
PMID: 7074401
DOI: 10.1007/BF03007119.
Malignant hyperthermia: a disease of specific myofiber type?.
Nelson T, SCHOCHET Jr S
Can Anaesth Soc J. 1982; 29(2):163-7.
PMID: 7066741
DOI: 10.1007/BF03007997.
Masseter spasm induced by succinylcholine in children: contracture testing for malignant hyperthermia: report of six cases.
Flewellen E, Nelson T
Can Anaesth Soc J. 1982; 29(1):42-9.
PMID: 7055743
DOI: 10.1007/BF03007947.
